How to Get Tresiba in Kentucky

What Is Tresiba and Why Kentucky Patients Request It

Tresiba is a once-daily basal insulin with a half-life of approximately 25 hours and a duration of action exceeding 42 hours, giving it the longest pharmacokinetic profile of any commercially available insulin. The DEVOTE trial (N=7,637, published in NEJM 2017) compared insulin degludec with insulin glargine U-100 in adults with type 2 diabetes at high cardiovascular risk. Degludec achieved a 40% lower rate of severe hypoglycemia versus glargine (rate ratio 0.60 to 95% CI 0.48-0.76, P<0.001 for superiority) while reaching non-inferior cardiovascular outcomes. [1]

That hypoglycemia advantage is what drives many Kentucky patients to request Tresiba specifically. Overnight lows are a real safety issue, particularly for patients living in rural counties with limited emergency access. Kentucky has 120 counties; more than 60 are classified as rural or frontier, making hypoglycemia events that require 911 response a genuine logistical problem.

The FDA approved insulin degludec in September 2015 for adults with type 2 diabetes, then broadened the label in January 2016 to include type 1 diabetes and pediatric patients down to age 1. [2] The approved concentrations are U-100 and U-200 FlexTouch prefilled pens.

Glycemic control data from the BEGIN trial program showed that degludec produced HbA1c reductions comparable to insulin glargine across multiple phase 3 studies, with consistent findings in the BEGIN ONCE LONG trial (N=1,030) showing a mean HbA1c reduction of 1.06 percentage points from baseline at 52 weeks. [3] For patients already well-controlled but struggling with nocturnal hypoglycemia, switching to degludec may reduce event frequency without sacrificing overall glycemic targets.

Kentucky Telehealth Rules for Tresiba Prescriptions

Kentucky fully permits telehealth prescribing of controlled and non-controlled medications, including Schedule III-V substances and standard prescription drugs like insulin degludec. Tresiba is not a controlled substance, so the prescribing pathway through telehealth is straightforward.

Under Kentucky Revised Statutes and the Kentucky Board of Medical Licensure guidelines, a prescriber conducting a telehealth visit must establish a valid patient-provider relationship before issuing a prescription. [4] That relationship can be established through a synchronous audio-visual visit, meaning a live video call qualifies. Asynchronous "questionnaire-only" prescribing of insulin products does not meet the standard of care for diabetes management.

Telehealth providers licensed in Kentucky, or holding a Kentucky telehealth interstate compact registration, may send a Tresiba prescription electronically to any Kentucky-licensed pharmacy, including mail-order pharmacies. The American Diabetes Association 2024 Standards of Care state that telehealth services "can improve access to diabetes care, particularly for underserved populations," specifically naming rural communities. [5]

A qualifying telehealth visit for Tresiba typically covers current fasting glucose readings or a recent HbA1c, prior insulin history, current medications, and a brief cardiovascular history given degludec's DEVOTE cardiovascular safety data. The visit takes 20-30 minutes on average. After the visit, the electronic prescription reaches the pharmacy the same day in most cases.

HealthRX Telehealth-to-Prescription Timeline for Kentucky Patients (estimated)

1. Schedule telehealth visit: same day to 48 hours
2. Synchronous video visit: 20-30 minutes
3. Electronic Rx sent to pharmacy: within 2 hours post-visit
4. Pharmacy processing and shipment: 1-3 business days for mail-order, same day for local retail
5. Total time from scheduling to insulin in hand: 2-5 business days

This timeline assumes no prior authorization is required. When private insurance mandates PA, add 3-10 business days for insurer review.

Who Can Prescribe Tresiba in Kentucky

Kentucky law permits prescribing of insulin degludec by physicians (MD and DO), advanced practice registered nurses (APRNs) with prescriptive authority, and physician assistants (PAs) acting within a collaborative practice agreement. All three provider types are legally authorized to prescribe Tresiba for both type 1 and type 2 diabetes.

APRNs in Kentucky have had independent prescriptive authority for Schedule II-V controlled substances since 2020, and prescribing non-controlled drugs like insulin has long been within their scope. [6] PAs must maintain a signed written agreement with a supervising physician, but that agreement does not limit the PA's ability to prescribe insulin.

Endocrinologists are the specialists most associated with complex insulin management, but primary care physicians, family medicine providers, internal medicine doctors, and APRNs in general practice all regularly prescribe basal insulin. The American Association of Clinical Endocrinology 2022 Diabetes Management Algorithm identifies basal insulin, including degludec, as appropriate for initiation in primary care when oral or non-insulin injectable therapy is insufficient. [7]

For patients seeking a new Tresiba prescription without an established endocrinologist, a telehealth provider or primary care physician is a practical and clinically appropriate starting point.

Labs and Documentation Required Before Starting Tresiba

Before a Kentucky prescriber issues a Tresiba prescription, they will need a current HbA1c (drawn within 3-6 months is standard), a fasting or random blood glucose reading, basic metabolic panel to assess renal function, and a medication list confirming prior insulin or diabetes drug history.

The ADA 2024 Standards of Care recommend checking renal function before adjusting insulin regimens because chronic kidney disease (CKD) alters insulin clearance. [5] Insulin degludec itself does not require dose adjustment for renal impairment per the FDA label, but CKD affects overall glycemic management. [2]

Thyroid function is not a prerequisite for Tresiba specifically, though many diabetes panels include TSH given the higher prevalence of thyroid disease in patients with autoimmune type 1 diabetes. A lipid panel is prudent in patients with type 2 diabetes given cardiovascular risk stratification, particularly in light of the DEVOTE trial's enrollment criteria (all participants had established CV disease or high CV risk). [1]

Patients switching from another basal insulin should have their most recent continuous glucose monitor (CGM) data or self-monitored blood glucose (SMBG) logs available. This data helps the prescriber set the correct starting degludec dose. The FDA label recommends a unit-for-unit conversion from insulin glargine U-100 or insulin detemir when switching, though some patients require a 10-20% dose reduction to account for degludec's greater potency at equivalent units. [2]

Kentucky Pharmacy Access for Tresiba

Tresiba is stocked at most major retail pharmacy chains operating in Kentucky, including CVS, Walgreens, Walmart Pharmacy, and Kroger Pharmacy. Independent pharmacies in Kentucky's rural counties may not carry it in stock but can order it within 1-2 business days through standard pharmaceutical distributors.

Mail-order pharmacies licensed in Kentucky, including those affiliated with major pharmacy benefit managers (PBMs) like Express Scripts and CVS Caremark, ship insulin degludec to Kentucky residential addresses. Cold-chain shipping for insulin is standard. Packages include insulated liners and gel packs. Orders placed Monday through Thursday typically arrive within 2-3 business days.

503A compounding pharmacies in Kentucky hold state licensure to compound insulin degludec preparations. [8] These pharmacies operate under USP <797> standards for sterile compounding and are licensed by the Kentucky Board of Pharmacy. Compounded insulin degludec would typically be prescribed for a patient with a documented need for a specific concentration or formulation not commercially available, though this pathway is less common than dispensing the branded Tresiba product directly.

The FDA database of registered drug establishments can be searched to verify that any 503A pharmacy filling a Kentucky prescription holds current registration. [9] Always confirm a compounding pharmacy's Kentucky Board of Pharmacy license at kbp.ky.gov before accepting a compounded insulin product.

Kentucky Insurance Coverage and Prior Authorization for Tresiba

Most commercial insurance plans operating in Kentucky place Tresiba on Tier 3 or Tier 4 of the formulary, triggering prior authorization requirements. Kentucky Medicaid (administered by managed care organizations including Aetna Better Health of Kentucky, Humana CareSource, Molina Healthcare of Kentucky, and WellCare of Kentucky) does not currently cover insulin degludec for type 1 or type 2 diabetes as of the most recent formulary review.

Prior authorization for Tresiba through commercial insurers in Kentucky generally requires documentation of the following: diagnosis of type 1 or type 2 diabetes with ICD-10 code, HbA1c above a threshold set by the insurer (commonly 7.5% or 8%), a record of at least one trial of a preferred formulary basal insulin (typically insulin glargine), and documentation of clinical reason for degludec specifically, such as recurrent hypoglycemia events or nocturnal hypoglycemia. [10]

The ADA position statement on insulin access states that "insulin affordability is a major barrier to adherence," and recommends that clinicians document hypoglycemia burden thoroughly to support PA requests. [11] A PA letter citing the DEVOTE trial's 40% hypoglycemia reduction finding, alongside the patient's own documented low glucose events, significantly strengthens the case.

Appeals are available when a PA is denied. Kentucky law requires insurers to provide a written explanation of denial and a clear appeals process. The Kentucky Department of Insurance handles consumer complaints related to coverage denials and can be contacted at doi.ky.gov.

Cost and Savings Programs for Tresiba in Kentucky

Without insurance, Tresiba U-100 FlexTouch (5 x 3 mL pens, 300 units each) retails at approximately $350-$530 at Kentucky pharmacies, depending on location and pharmacy. The U-200 FlexTouch pen contains 600 units per pen and offers a higher unit-per-dollar value for patients requiring more than 20 units per day.

Novo Nordisk operates the Novo Nordisk Patient Assistance Program (PAP), which provides free Tresiba to uninsured patients meeting income criteria (generally at or below 400% of the federal poverty level). Applications are submitted through novo-pi.com or by calling 1-844-668-6463. [12]

The Novo Nordisk savings card (for commercially insured patients) reduces out-of-pocket cost to as low as $99 per month for eligible patients. This card does not apply to Medicare Part D or Medicaid.

GoodRx, NeedyMeds, and the Kentucky Rx Card are discount programs available at participating Kentucky pharmacies that may reduce Tresiba cost by 15-40% off retail price. These are not insurance and do not count toward deductibles, but they are immediately usable with no application process.

Transferring an Existing Tresiba Prescription to Kentucky

Patients relocating to Kentucky with an existing Tresiba prescription from another state can transfer it to a Kentucky-licensed pharmacy if refills remain on the prescription. Kentucky pharmacies accept transfers from out-of-state pharmacies for non-controlled substances.

The receiving pharmacy contacts the dispensing pharmacy directly to complete the transfer. Patients should inform the receiving pharmacist of the prescribing provider's contact information in case a new prescription is needed after the original expires or runs out of refills. Insulin prescriptions in most states, including Kentucky, are valid for 12 months from the date written and allow the number of refills specified by the prescriber.

If refills are exhausted or the prescription has expired, a new prescription from a Kentucky-licensed provider is required. A telehealth provider licensed in Kentucky can issue a new prescription after a qualifying visit, which allows continuation of therapy without a gap. The American Diabetes Association recommends against insulin interruptions given the risk of diabetic ketoacidosis in type 1 patients and hyperglycemic decompensation in type 2 patients. [5]

Monitoring Tresiba After Starting in Kentucky

After initiating insulin degludec, patients should check fasting blood glucose daily for the first 2-4 weeks while the dose is being titrated. Degludec reaches steady-state plasma concentration in approximately 3-4 days after dose initiation or change, meaning dose adjustments should not be made more frequently than every 3-4 days to allow accurate assessment of effect. [2]

The FDA label recommends titrating the degludec dose by 2 units every 3 days based on fasting glucose until target is reached. Many endocrinologists use a target fasting glucose of 80-130 mg/dL per ADA 2024 Standards, though individual targets vary by age, hypoglycemia history, and comorbidities. [5]

CGM use alongside degludec therapy provides a clearer picture of nocturnal glucose patterns than SMBG alone. The SWITCH 2 trial (N=721) showed that patients with type 2 diabetes on degludec experienced 36% fewer hypoglycemic episodes on CGM compared to those on glargine U-100 over 32 weeks, with a between-group difference that reached statistical significance (P<0.001). [13]

Patients should also be counseled on injection site rotation. Degludec is injected subcutaneously into the abdomen, thigh, or upper arm. Consistent site rotation reduces lipohypertrophy, which impairs insulin absorption and contributes to unpredictable glucose variability. The American Diabetes Association recommends systematic site rotation within each anatomical region rather than random switching between regions. [14]

Follow-up HbA1c testing is standard at 3 months after initiating or significantly adjusting degludec dose. A single HbA1c check 3 months post-initiation confirms whether the titration protocol has achieved target glycemic control, and guides the decision to continue, adjust, or add a prandial insulin component.